FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright

Ocugen, Inc. (NASDAQ:OCGN) – Equities researchers at HC Wainwright cut their FY2029 EPS estimates for Ocugen in a research report issued on Monday, September 28th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.05 for the year, down from their previous forecast of $0.06. The consensus estimate for Ocugen’s current full-year earnings is ($0.25) per share.

OCGN has been the topic of several other research reports. Wall Street Zen downgraded shares of Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded shares of Ocugen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Ocugen has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Ocugen Stock Performance

Shares of Ocugen stock opened at $1.03 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 4.17. The stock’s fifty day moving average is $1.23 and its two-hundred day moving average is $1.45. Ocugen has a 52 week low of $0.97 and a 52 week high of $2.73. The company has a market capitalization of $349.28 million, a PE ratio of -3.96 and a beta of 2.20.

Ocugen (NASDAQ:OCGN) last released its earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $0.89 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of OCGN. Engineers Gate Manager LP raised its position in shares of Ocugen by 70.2% during the 2nd quarter. Engineers Gate Manager LP now owns 18,368 shares of the company’s stock valued at $28,000 after buying an additional 7,577 shares during the period. NewEdge Advisors LLC increased its stake in Ocugen by 42.4% during the second quarter. NewEdge Advisors LLC now owns 237,180 shares of the company’s stock worth $363,000 after acquiring an additional 70,585 shares during the last quarter. AXQ Capital LP purchased a new stake in Ocugen in the second quarter valued at $65,000. Headlands Technologies LLC raised its holdings in Ocugen by 527.1% in the 2nd quarter. Headlands Technologies LLC now owns 511,575 shares of the company’s stock valued at $783,000 after buying an additional 429,997 shares during the period. Finally, Two Sigma Securities LLC lifted its position in Ocugen by 116.9% in the second quarter. Two Sigma Securities LLC now owns 156,027 shares of the company’s stock valued at $239,000 after buying an additional 84,100 shares during the last quarter. Institutional investors and hedge funds own 10.27% of the company’s stock.

Insider Activity at Ocugen

In other news, CEO Shankar Musunuri sold 57,264 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $1.12, for a total value of $64,135.68. Following the transaction, the chief executive officer directly owned 1,088,035 shares of the company’s stock, valued at approximately $1,218,599.20. This trade represents a 5.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.95% of the company’s stock.

Ocugen News Roundup

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised multiple EPS forecasts. The firm reduced its projected losses for Q4 2026, FY2026, Q2-Q4 2027, FY2027 and FY2028. Its FY2030 forecast also increased to $0.99 per share from $0.98, suggesting improved long-term expectations for Ocugen’s commercial potential. HC Wainwright earnings estimates for Ocugen
• Positive Sentiment: Ocugen will present its modifier gene-therapy platform at upcoming scientific conferences. The events may increase investor and scientific awareness of the company’s programs targeting blindness diseases and could provide a forum for pipeline updates. Ocugen to Participate in Upcoming Scientific Conferences
• Neutral Sentiment: Management is scheduled to participate in investor and industry conferences in October. These appearances could generate future catalysts, but the announcements do not include new clinical results, regulatory decisions or partnership terms. Ocugen to Participate in Upcoming October Investor and Industry Conferences
• Negative Sentiment: Ocugen is still expected to report substantial losses in the near term. HC Wainwright projects negative EPS through FY2028, and lowered its FY2029 estimate to $0.05 from $0.06. The company’s recent quarterly loss also exceeded analyst expectations, reinforcing profitability and execution risks.

About Ocugen

Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and other serious medical conditions. The company’s ophthalmology pipeline includes modifier gene therapies designed to address inherited retinal diseases, including retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration.

Ocugen’s leading candidates include OCU400, an investigational gene therapy for certain inherited retinal diseases, and OCU410 and OCU410ST, investigational therapies being developed for geographic atrophy and Stargardt disease, respectively.